Clark J N, Pulliam J D, Daurio C P
Merck, Sharp & Dohme Research Laboratories, Division of Merck & Co Inc, Rahway, NJ 07065-0900.
Am J Vet Res. 1992 Apr;53(4):608-12.
To determine the safety of a new combination of ivermectin and pyrantel (as pamoate salt) in a novel beef-based chewable tablet formulation, 3 tolerance trials were conducted and included growing dogs, pups, and breeding adult dogs. Growing dogs, given the combination orally for 5 consecutive days at recommended dosages (5 mg of pyrantel/kg of body weight, 6 micrograms of ivermectin/kg) or at twice the pyrantel dosage in combination with the recommended dosage of ivermectin, had no adverse effects. The combination also was administered to 6-week-old pups at 1, 3, and 5 times the recommended dose on 3 successive days for 3 times in 1 month. Compared with age-matched controls, treatment had no effect on clinical status, growth rate, or gross or histologic features. Breeding male and female dogs given the combination at 3 times the recommended dose for extended periods had no adverse effects, and prevalence of abnormalities in the offspring was not greater than that in nonmedicated controls.
为确定伊维菌素与噻嘧啶（作为双羟萘酸盐）新组合的新型牛肉味咀嚼片制剂的安全性，进行了3次耐受性试验，受试动物包括生长犬、幼犬和成年繁殖犬。生长犬连续5天按推荐剂量（5毫克噻嘧啶/千克体重，6微克伊维菌素/千克）口服该组合制剂，或按噻嘧啶剂量加倍并结合伊维菌素推荐剂量口服，均未出现不良反应。该组合制剂还在1个月内连续3天，以推荐剂量的1倍、3倍和5倍给予6周龄幼犬，共给药3次。与年龄匹配的对照相比，治疗对临床状况、生长速率或大体或组织学特征均无影响。长期给予推荐剂量3倍的该组合制剂的成年繁殖公犬和母犬均未出现不良反应，且后代异常发生率不高于未用药的对照。
